In November 2013, we founded Editas Medicine with $43 million in financing from three venture capital firms. Just a half a year later, Emmanuelle co-founded another company, CRISPR Therapeutics, with an initial $25 million bankroll, and in November 2014, a third company, Intellia Therapeutics, joined the scene with $15 million in Series A funding. By the end of 2015, these three companies would raise well over half a billion dollars more for research and development of therapies to target numerous disorders, from cystic fibrosis and sickle cell disease to Duchenne muscular dystrophy and a
...more
